1 BTC
=
- USD
Biodesix, Inc. Common Stock
As of May 30, 2026 at 24:05 UTC
Chart
About Biodesix, Inc. Common Stock
Biodesix Inc is a diagnostic solutions company with a focus on lung disease. The Company has a single operating segment focused on providing diagnostic testing services to customers. It provides biopharmaceutical companies with services that include diagnostic research, clinical trial testing, and the discovery, development, and commercialization of companion diagnostics. The revenue is derived from two sources: providing diagnostic testing services associated with blood-based lung and COVID tests; and providing biopharmaceutical companies with services generally provided outside the clinical setting and governed by individual contracts with third parties, as well as the development and commercialization of companion diagnostics.
Market Statistics
Trading Metrics
How to Buy BDSX
Create Your Account
Sign up, deposit BTC, and transfer it to your Unified Trading Account. It only takes a moment.
Start Your Trade
From Terminal, click Trade Now on the asset you want to buy. You'll be purchasing its tokenized asset.
Buy BDSX
Enter the amount and confirm your purchase. That's it! You'll see the impact of the trade in your Unified Trading Account.
New to Tokenized Assets? Learn more in our Help Center.
Latest News
5 articlesBiodesix, Inc. (Nasdaq: BDSX) announced that its leadership team will participate in three upcoming investor conferences in May and June 2026, including Craig-Hallum, William Blair Growth Stock Conference, and TD Cowen Annual Tools/Dx Revolution. The company will hold 1x1 meetings and present at select events, with presentations available for webcast replay.
Biodesix, Inc. (Nasdaq: BDSX) announced it will release first quarter 2026 financial results on May 4, 2026, after market close, followed by a management conference call and webcast at 4:30 p.m. ET to discuss results and provide a business update.
Biodesix, Inc. announced preliminary Q4 2025 revenue of $28.8 million (41% increase) and full-year 2025 revenue of $88.5 million (24% increase). The company affirmed guidance for Adjusted EBITDA positivity in Q4 2025. Management will participate in investor conferences in March 2026.
Biodesix reported estimated Q4 2025 revenue of $28.8 million (41% increase) and full-year 2025 revenue of $88.5 million (24% increase). The company affirmed guidance for Adjusted EBITDA positivity in Q4 and plans to present clinical utility data for its Nodify Lung tests at upcoming scientific meetings.
Biodesix reported Q4 2025 revenue of $28.8 million (41% increase) and full-year revenue of $88.5 million (24% increase), exceeding guidance. Lung Diagnostics revenue grew 47% in Q4 driven by increased test volumes and reimbursement expansion. The company affirmed expectations for positive Adjusted EBITDA in Q4 2025.